Mr. Johnson has over twenty-five years of biopharma experience with a solid track record of leading multi-billion commercial franchises. Bruce has experience in developing and launching new products, establishing new capabilities, and improving profitability. He has experience leading turnarounds, as well as starting, building and launching new businesses. He has worked in the oncology area for many years and successfully led product launches across a variety of disease areas to include: breast, lung, kidney, melanoma and neuroendocrine tumors, as well as a wide range of hematologic malignancies and rare diseases. He was directly involved in the product launch for Venclexta, Zometa, Sandostatin/Sandostatin LAR, Jakavi, Gleevec/Glivec, Tasigna, Afinitor and Rydapt. He has worked for several organizations to include: Memorial Sloan Kettering, Sandoz, Novartis, AbbVie and more recently Cancer Expert Now, Inc., a digital health company, where he was Executive Vice President and Chief Commercial Officer and helped lead the organization to achieve national recognition by Inc. Magazine as one of the Top 500 fastest growing small companies in America. His education includes graduate work at Columbia University in Biochemistry and Molecular Biology and at Rutgers University School of Management in Marketing and Finance. He received a BA in Microbiology at Miami University in Oxford, Ohio.